If we don’t incentivize continued investments in drug research and development, we’ll lose out on new therapies that don’t ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Biden-era ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

A new fight is brewing over the Medicare drug price negotiation program after the Trump administration proposed to consider ...

Guidelines aimed at increasing transparency about how the regulator will evaluate pharmaceutical pricing, official says ...

Drug development is a decade-long, costly process replete with failures. If we don’t incentivize investments in research and ...

Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.

Trump’s “big beautiful” bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

The sweeping One Big Beautiful Bill Act, signed into federal law July 4, amended CMS’ drug price negotiations authority that could absolve nearly $5 billion in projected savings, according to the ...

The Senate passed its version of the GOP megabill on Tuesday, and big players across the health care industry have been quick ...

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic ...